ONO PHARMACEUTICAL CO.,LTD.

May 14, 2020

ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand the Use for Treatment of Previously Untreated Unresectable Advanced or Recurrent Gastric Cancer in Japan

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; "ONO") announced today that ONO has submitted a supplemental application for Opdivo® (generic name: nivolumab) Intravenous Infusion ("Opdivo"), a human anti-human programmed cell death-1 (PD-1) monoclonal antibody in Japan, to expand the use for the treatment of patients with unresectable advanced or recurrent gastric cancer who have not been previously treated, for a partial change in approved items of the manufacturing and marketing approval.

This application is based on the data from a multi-center, randomized Phase II / III clinical study (ATTRACTION-4 study: ONO-4538-37) evaluating Opdivo in combination with chemotherapy versus placebo in combination with chemotherapy in patients with previously untreated unresectable advanced or recurrent gastric cancer (including esophago-gastric junction cancer) that is negative for human epidermal growth factor receptor 2 (HER2).

It is estimated that about 115,000 new cases are diagnosed with gastric cancer per year in Japan (about 1,033,000 cases worldwide) and approximately 48,000 deaths (about 782,000 worldwide) per year resulting from this disease[1)], which is the 2nd most common type of cancer after lung cancer in Japan. As there has been little progression in the standard of care of first-line chemotherapy for the HER 2-negative unresectable, advanced, recurrent gastric cancer in the past decade in Japan, an innovative treatment option is needed in this patient population.

1) Globocan 2018; Stomach Cancer: Estimated cancer incidence, mortality and prevalence worldwide. World Health Organization. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf

About ATTRACTION-4 study (ONO-4538-37)

This study is a multi-center, randomized, Phase II / III clinical study (ATTRACTION-4 study: ONO-4538-37) evaluating Opdivo in combination with chemotherapy (oxaliplatin + S-1 or capecitabine) compared to placebo in combination with chemotherapy in patients with HER2-negative previously untreated unresectable advanced or recurrent gastric cancer (including esophago-gastric junction cancer). Patients received Opdivo 360 mg or placebo every 3 weeks until disease progression or unacceptable toxicity is observed. The primary endpoints of this study are progression-free survival (PFS) and overall survival (OS). The secondary endpoint is overall response rate (ORR).

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response by blocking the

interaction between PD-1 and its ligands. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers since the approval for the treatment of melanoma in Japan in July 2014. Opdivo is currently approved in more than 65 countries, including Japan, South Korea, Taiwan, China, the US and European Union.

In Japan, ONO launched Opdivo for the treatment of unresectable melanoma in September 2014. Thereafter, Opdivo received an approval for additional indications of unresectable, advanced or recurrent non-small cell lung cancer in December 2015, unresectable or metastatic renal cell cancer in August 2016, relapsed or refractory classical Hodgkin lymphoma in December 2016, recurrent or metastatic head and neck cancer in March 2017, unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy in September 2017, unresectable advanced or recurrent malignant pleural mesothelioma which has progressed after chemotherapy and adjuvant treatment of melanoma in August 2018, and microsatellite instability high (MSI-High) unresectable advanced or recurrent colorectal cancer that has progressed following chemotherapy and unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy in February 2020.

In addition, ONO is conducting clinical development program including esophago-gastric junction cancer, small cell lung cancer, hepatocellular carcinoma, glioblastoma, urothelial cancer, ovarian cancer, bladder cancer, pancreatic cancer, biliary tract cancer, etc.

About the ONO and Bristol-Myers Squibb Collaboration

In 2011, through a collaboration agreement with Bristol-Myers Squibb (BMS), ONO granted BMS its territorial rights to develop and commercialize Opdivo globally except in Japan, South Korea and Taiwan, where ONO had retained all rights to Opdivo except the US at the time. In July 2014, ONO and BMS further expanded the companies' strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies – as single agent and combination regimens – for patients with cancer in Japan, South Korea and Taiwan.

Contact
Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono.co.jp